Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma

SHENG-KAI LIANGMIN-SHU HSIEHMENG-RUI LEELI-TA KENGJEN-CHUNG KOJIN-YUAN SHIH2020-03-052020-03-0520171949-2553https://www.scopus.com/inward/record.uri?eid=2-s2.0-85032282584&doi=10.18632%2foncotarget.19563&partnerID=40&md5=621058f081bd7ee1e1c99e145df80e22https://scholars.lib.ntu.edu.tw/handle/123456789/470779Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinomajournal article10.18632/oncotarget.195632-s2.0-85032282584